Abstract CT069: Randomized phase 3 study (STARBOARD) evaluating encorafenib (enco) + binimetinib (bini) + pembrolizumab (pembro) for first-line treatment of unresectable locally advanced or metastatic BRAF V600-mutant melanoma
Year: 2023
Type: conference-abstract
Source: Cancer Research
Institutions: University Hospital Zurich, Institut Gustave Roussy, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital, University of Tennessee Medical Center, Sarah Cannon, Tennessee Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W4365512752